Q-omics provides the consensus-scored H2AC21 profile across patient tissues and cancer cell-line models. H2AC21 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, H2AC21 is differentially expressed in 12, with the highest sampling consensus in BRCA. Additionally, H2AC21 protein abundance shows 22,846 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, BRCA, and HNSC as cancer lineages where H2AC21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2AC21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2AC21 survival associations across molecular data types. H2AC21 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2AC21 RNA expression–survival associations across cancer types. High H2AC21 expression shows unfavorable associations in ACC, LUAD, LGG, KIRP, THCA and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for H2AC21 RNA expression.
This table summarizes H2AC21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in BRCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for H2AC21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2AC21 shows lower tumor expression in KICH and higher tumor expression in BRCA, LIHC, UCEC, LUSC and LUAD. The BRCA box plot shows higher H2AC21 RNA expression in tumor versus normal tissue (log2 FC = +0.442, t-test p < 0.001).
This table shows molecular features associated with H2AC21 in patient tissues and cancer cell lines. In patient samples, H2AC21 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, H2AC21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
